Ernexa Therapeutics Appoints Dr. Robert J. Spiegel to Board
Ernexa Therapeutics has appointed Robert J. Spiegel, M.D., FACP, to its Board of Directors. The company is targeting an IND for ERNA-101 in Q4 2026 and a first-in-human study in Q1 2027.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.
News Feed
2 results loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
Ernexa Therapeutics appoints Robert J. Spiegel to board
Ernexa Therapeutics appointed biopharmaceutical executive Robert J. Spiegel, M.D., FACP, to its Board of Directors. The company said the appointment strengthens the board as it advances ERNA-101 toward clinical development.